# Bellicum Pharmaceuticals Inc (BLCM)

Prohost Biotech

Dec 28, 2018

5

Bellicum Pharmaceuticals (BLCM): The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on studies of BPX-501 in the U.S. The decision follows consultation with the FDA and agreement...

Bellicum Pharmaceuticals: The FDA Lifted the Clinical Hold on BPX-501 Clinical Trial

Prohost Biotech

Apr 12, 2018

4m

8

The Treatment is Not A New Way as Being Stated, It is Only the Target, Which Has Been Changed Outstanding news announced that leukemia patients who relapsed after being treated with the chimeric rec...

A New Trial Demonstrates Promising Results of CAR T Targeting CD-22 for Leukemia Patients.

Coming Soon... The Week in Review #3 Gilead Acquisition - Rallying by Association - Improving on Cancer Treatments... ...

Prohost Biotech

Nov 21, 2017

Gilead's Acquisition Effect on Other CAR-T Developers' Stocks

Prohost Biotech

Sep 4, 2017

7

When what you predicted, preached, and wished are realized, this is good news. Today’s news is bringing all Prohost predictions into realization, Yes, Kite (KITE) is on its way to be acquired by Gile...

Gilead to Acquire Kite and Juno Stock Rallied Too

THE WEEK IN REVIEW Wall Street As we said in yesterday’s article posted under Today’s Highlights, stocks can plummet at any time, regardless of whether they have the best or the worst grades for their...

Prohost Biotech

Aug 28, 2017

The STAR of the Week

IMPRESSIVE RESULTS? Bellicum Pharmaceuticals’ (BLCM) drug BPX-501 is described as a safe and effective product that can offer children with cancer and other serious diseases the opportunity to beat t...

Prohost Biotech

Aug 20, 2017

About Bellicum Pharmaceuticals' Product BPX-501

Prohost Biotech

Jun 27, 2017

4

AT ASCO CAR-T Was Created to Stay BlueBird Bio CAR-T Results Bluebird Bio (BLUE) presentation was well received at ASCO after the firm stated results demonstrating that all the 15 evaluable patients i...

Bluebird Flies Sky-High with Its CAR-T Wings

It is obvious that the CAR-T approach to cancer treatment is here to stay and to change the way cancer has been managed for decades. Attempts to improve the novel elegant procedure safety profile and...

Prohost Biotech

Jun 7, 2017

CAR-T Great News and About the Biotech Sector in General

Prohost Letter #407 AT A GLANCE - Firms Added to Prohost Portfolio PROHOST IS PICKING NEUROCRINE BIOSCIENCES On March 27, a few days before the FDA approves Neurocrine’s (NBIX) drug Ingrezza, (valbe...

Prohost Biotech

Jun 1, 2017

Prohost Letter #407

Making Sure that CAR-T Therapy for Cancer Succeeds Academic Researchers Identify a New Process to Raise Natural Armies of Cancer-Targeting T Lymphocytes Outside the Body Unleashing More Power to the I...

Prohost Biotech

Apr 20, 2017

Academic Researchers Improve on CAR-T Immunotherapy. Guess Who the Beneficiaries Are?

Prohost Letter #404 Part 2 Synthetic Biology (2) A Brief History DNA is the software of life. This is how Synthetic Genomics firm, which we believe is now is the leading biotech firm for applied synth...

Prohost Biotech

Feb 23, 2017

Prohost Letter #404 Part 2

Bellicum Pharmaceuticals (BLCM) announced results from the BP-004 multicenter clinical trial for children with Primary Immune Deficiencies (PIDs) and hemoglobinopathies. The candidates received an add...

Prohost Biotech

Feb 6, 2017

Bellicum Is Outperforming and So Should Be Its Stock

Prohost Biotech

Dec 5, 2016

2

Immunotherapy Engineered T-Cell Therapy Is Here to Stay Articles aimed at undermining the value of the firms’ chimeric antigen receptor T (CAR T) cells as immunotherapy for cancer are less and less co...

Biotech Firms with Approaches Born To Stay and Succeed

Le Compa G non Part 2 Wednesday June 22, 2016 From the American Society of Clinical Oncology (ASCO) Checkpoint inhibitors the CAR T Approach Adoptive cell therapy Oncolytic virus ther...

Prohost Biotech

Aug 10, 2016

Le CompaGnon Part 2

Prohost Letter #393 IMMUNOTHERAPY - PROHOST PORTFOLIO - NEW PICKS? - A Brief Reminder of the CAR T –TCR Immunotherapy Approaches In this issue we continue our journey inside the territory of cancer...

Prohost Biotech

Jun 23, 2016

Prohost Letter #393

Prohost Letter #391 Frightened by the Market and Politicians’ Debates, Not the Drug Industry, Investors are Fleeing the Biotechnology Sector 1. A fruitless debate over the high prices of drugs 2. Th...

Prohost Biotech

Mar 4, 2016

Prohost Letter #391

Prohost Letter #388 TOPICS - 1. AN INDISPENSABLE SHORT INTRODUCTION 2. GENE EDITING 3. GENE THERAPY 4. CANCER IMMUNOTHERAPY 1. GENE EDITING Exon Skipping: Biomarin (BMRN); Sarepta (SRPT); These firms...

Prohost Biotech

Feb 1, 2016

Prohost Letter #388

Prohost Letter #383 The Market - Recent tails about the market and the biotech sector are true thrillers. By true we mean no-fiction. The accounts lack common sense. Professionals' interpretations of...

Prohost Biotech

Dec 2, 2015

Prohost Letter #383

Prohost Biotech

Sep 25, 2015

8

The moment the new IPO NantKwest (NK) landed in the town of publicly traded firms, some called it the “New Golden Boy”. During the IPO, investors who knew about this firm and were waiting for that day...

NantKwest Inc: A Novel Breathtaking Immunotherapy for Cancer?